Product Images Clopidogrel
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 10 images provide visual information about the product associated with Clopidogrel NDC 71335-0080 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 1 - clopidogrel fig1
This is a figure showing the exposure to Clopidogrel Active Metabolite after taking multiple doses of Clopidogrel Bisulfate alone or with Proton Pump Inhibitors (PPIs). The effect of co-administered PPIs on the active metabolite AUC is shown in mean and 90% confidence interval. The specific PPIs are listed and their corresponding change relative to clopidogrel bisulfate administered alone is plotted on the x-axis. No other information is available.*
Figure 2: Cardiovascular Death, Myocardial Infarction, and Stroke in the CURE Study - clopidogrel fig2
This appears to be a table showing the cumulative event rate percentage for different treatments (Plagebo + Aspirin and Clopidogrel Bisulfate + Aspirin) for cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. It also includes a statistic showing statistical significance (P = 0.00009).*
Figure-3 - clopidogrel fig3
Figure 4: Cumulative Event Rates for Death in the COMMIT Study - clopidogrel fig4
This text appears to be a chart or table showing the number of deaths before the first discharge, with statistics for a placebo group and a group taking the drug clopidogrel. It includes percentages and a proportional risk reduction of 7%, with a p-value of 0.03. The chart also includes a timeline of days since randomization up to 28 days.*
Figure 5: Cumulative Event Rates for the Combined Endpoint Re-Infarction, Stroke or Death in the COMMIT Study - clopidogrel fig5
This is a medical study comparing the effects of Placebo and Clopidogrel. It reports the number of events and the percentage of patients with events in each group. There is also a graph showing the number of days since randomization and events related to death, re-infarction, and stroke.*
Figure 6: Effects of Adding Clopidogrel Bisulfate to Aspirin on the Combined Primary Endpoint across Baseline and Concomitant Medication Subgroups for the COMMIT Study - clopidogrel fig6
Figure 7: Fatal or Non-Fatal Vascular Events in the CAPRIE Study - clopidogrel fig7
This appears to be a graph that shows the cumulative event rate (in percentage) of fatal or non-fatal vascular events for Aspirin and Clopidogrel Bisultate over a period of 36 months of follow-up. There are time increments divided into months, from 0 to 36, and the vertical axis measures the cumulative event rate.*
Figure 8: Hazard Ratio and 95% CI by Baseline Subgroups in the CAPRIE Study - clopidogrel fig8
This text seems to be a table or graph showing the number of patients with stroke, MI, and PAD under Qualifying Condition and their treatment with Clopidogrel Bisulfate and Aspirin. It also shows the percentage of patients who were given Clopidogrel Bisulfate and Aspirin, as well as the hazard ratio. The graph shows how Clopidogrel Bisulfate and Aspirin fare against each other in terms of efficacy in patients with the mentioned conditions.*
Chemical Structure - clopidogrel str
Label Image - lbl713350080
This is a medication description for Clopidogrel, a pink round tablet of 75mg used to prevent blood clots. It is produced by Aurobindo Pharma Limited and is equivalent to Plavix. It should be stored at a temperature of 20°-25°C (68°-77°F) and comes in a package of 90 tablets.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.